Loomis Sayles & Co. L P Trims Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Loomis Sayles & Co. L P reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,253,353 shares of the medical research company’s stock after selling 44,659 shares during the period. Thermo Fisher Scientific accounts for about 70.4% of Loomis Sayles & Co. L P’s holdings, making the stock its 25th biggest holding. Loomis Sayles & Co. L P’s holdings in Thermo Fisher Scientific were worth $652,032,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 41.5% during the 4th quarter. NEOS Investment Management LLC now owns 23,893 shares of the medical research company’s stock valued at $12,430,000 after buying an additional 7,002 shares during the period. UniSuper Management Pty Ltd raised its position in Thermo Fisher Scientific by 3.7% in the fourth quarter. UniSuper Management Pty Ltd now owns 161,011 shares of the medical research company’s stock valued at $83,763,000 after purchasing an additional 5,716 shares during the period. Sava Infond d.o.o. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $1,540,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Thermo Fisher Scientific by 15.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,575,054 shares of the medical research company’s stock worth $837,960,000 after purchasing an additional 214,985 shares during the last quarter. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its holdings in Thermo Fisher Scientific by 13.8% in the 4th quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 103,396 shares of the medical research company’s stock valued at $53,790,000 after buying an additional 12,551 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Citigroup lowered their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Morgan Stanley increased their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research report on Friday, January 10th. Finally, Bank of America cut their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $653.23.

Thermo Fisher Scientific Trading Down 0.2 %

NYSE TMO opened at $513.40 on Thursday. The firm’s fifty day moving average price is $543.80 and its 200 day moving average price is $553.93. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market capitalization of $193.68 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.41%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 in the last 90 days. 0.34% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.